WO1997025427A1 - Beta-chemokine, h1305 (mcp-2) - Google Patents
Beta-chemokine, h1305 (mcp-2) Download PDFInfo
- Publication number
- WO1997025427A1 WO1997025427A1 PCT/US1997/000379 US9700379W WO9725427A1 WO 1997025427 A1 WO1997025427 A1 WO 1997025427A1 US 9700379 W US9700379 W US 9700379W WO 9725427 A1 WO9725427 A1 WO 9725427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- nucleotide sequence
- nucleotide
- seq
- sequence
- Prior art date
Links
- 102000001902 CC Chemokines Human genes 0.000 title description 2
- 108010040471 CC Chemokines Proteins 0.000 title description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 title description 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 107
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 31
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 31
- 239000002157 polynucleotide Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 96
- 239000003146 anticoagulant agent Substances 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000002785 anti-thrombosis Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108010009298 lysylglutamic acid Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 2
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 2
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 2
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 description 2
- UAXIKORUDGGIGA-DCAQKATOSA-N Asp-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O UAXIKORUDGGIGA-DCAQKATOSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HMWBPUDETPKSSS-DCAQKATOSA-N Cys-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CCCCN)C(=O)O HMWBPUDETPKSSS-DCAQKATOSA-N 0.000 description 2
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 2
- SYDJILXOZNEEDK-XIRDDKMYSA-N Glu-Arg-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SYDJILXOZNEEDK-XIRDDKMYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 2
- PPQRKXHCLYCBSP-IHRRRGAJSA-N Leu-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N PPQRKXHCLYCBSP-IHRRRGAJSA-N 0.000 description 2
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 2
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 2
- MTBLFIQZECOEBY-IHRRRGAJSA-N Lys-Met-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O MTBLFIQZECOEBY-IHRRRGAJSA-N 0.000 description 2
- UFOWQBYMUILSRK-IHRRRGAJSA-N Met-Lys-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 UFOWQBYMUILSRK-IHRRRGAJSA-N 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- JIYJYFIXQTYDNF-YDHLFZDLSA-N Phe-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N JIYJYFIXQTYDNF-YDHLFZDLSA-N 0.000 description 2
- XZQYIJALMGEUJD-OEAJRASXSA-N Phe-Lys-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZQYIJALMGEUJD-OEAJRASXSA-N 0.000 description 2
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 2
- UQTNIFUCMBFWEJ-IWGUZYHVSA-N Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O UQTNIFUCMBFWEJ-IWGUZYHVSA-N 0.000 description 2
- DGOJNGCGEYOBKN-BWBBJGPYSA-N Thr-Cys-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)O DGOJNGCGEYOBKN-BWBBJGPYSA-N 0.000 description 2
- CWSIBTLMMQLPPZ-FXQIFTODSA-N Val-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N CWSIBTLMMQLPPZ-FXQIFTODSA-N 0.000 description 2
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- -1 sulfopropyl Chemical group 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000491 effect on chemotaxis Effects 0.000 description 1
- 230000000482 effect on migration Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- DVCSNHXRZUVYAM-BQBZGAKWSA-N leu-asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O DVCSNHXRZUVYAM-BQBZGAKWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to HI 305 proteins, nucleic acids encoding such proteins, and methods of treatment using such proteins.
- Chemokines are a subclass of cytokines which cause the directed migration or chemotaxis of particular cell populations either to or away from higher concentrations of the chemokine. Many chemokines have been identified which cause migration of major blood cell populations. These factors may be useful for directing the migration of cell populations to areas of desired action or away from areas of unwanted action. It would, therefore, be desirable to identify new chemokines and polynucleotides encoding them.
- HI 305 polynucleotide encoding HI 305 and active fragments thereof are disclosed.
- HI 305" is used throughout the present specification to refer to both proteins and polynucleotides encoding those proteins and to refer to proteins and polynucleotides from all mammalian species.
- the present invention provides an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
- Polynucleotides comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 47 to nucleotide 373 are particularly preferred.
- the polynucleotide of the invention encodes a protein having HI 305 activity.
- the polynucleotide is operably linked to an expression control sequence.
- Host cells transformed with the polynucleotides of the invention are also provided, including mammalian cells.
- Processes are also provided for producing a HI 305 protein, said processes comprising: (a) growing a culture of the host cell of the invention in a suitable culture medium; and
- Isolated HI 305 protein is also provided which comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2: and
- compositions which comprise an antibody which specifically reacts with a H1305 protein of the invention.
- Methods of treating a mammalian subject comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a HI 305 protein.
- SEQ ID NO: l provides the nucleotide sequence of a cDNA encoding the H1305 protein.
- SEQ ID NO:2 provides the amino acid sequence of the HI 305 protein predicted from the DNA coding sequence.
- the amino acid sequence of HI 305 contains known chemokine sequence motifs and shows homology with known chemokines.
- HI 305 protein of less than full length are encompassed within the present invention and may be produced by expressing a corresponding fragment of the polynucleotide encoding the HI 305 protein (SEQ ID NO: l). These corresponding polynucleotide fragments are also pan of the present invention.
- Modified polynucleotides as described above may be made by standard molecular biology techniques, including site-directed mutagenesis methods which are known in the an or by the polymerase chain reaction using appropriate oligonucleotide primers.
- a mature form of the H1305 protein if it differs from the full-length sequence of SEQ ID NO:2, can be produced by expression of the full-length polynucleotide in an appropriate cell line.
- a protein has "H1305 activity” if it either (1) displays chemoattractant or chemotactic activity in a chemoattraction or chemotaxis assay (preferably an assay in which the corresponding species full- length HI 305 is active), or (2) displays biological activity in a factor-dependent cell proliferation assay (preferably an assay in which the corresponding species full-length H1305 is active), or (3) displays activity in the induction of lymphokine production or effector function in an immune cell functional assay. Examples of effector function include, without limitation, tumoricidal activity, granule release, adhesion molecule expression, and the like. Activity may be monitored using assays known in the art.
- Chemoattractant or chemotactic activity can also be measured in vivo by injecting protein at a particular site and performing a histological examination of the cell types that migrate to the site of injection.
- H1305 protein or fragments thereof having H1305 activity may be fused to carrier molecules such as immunoglobulins.
- HI 305 protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin.
- the invention also encompasses allelic variations of the nucleotide sequence as set forth in SEQ ID NO: l , that is, naturally-occurring alternative forms of the isolated polynucleotide of SEQ ID NO: l which also encode HI 305 or HI 305 proteins having HI 305 activity.
- isolated polynucleotides which hybridize to the nucleotide sequence set forth in SEQ ID NO: l under highly stringent (e.g., 0.2xSSC at 65°C). stringent (e.g. 4xSSC at 65 C C or 50% formamide and 4xSSC at 42°C), or relaxed (e.g., 4xSSC at 50°C or 30-40% formamide and 4xSSC at 42°C) conditions.
- Isolated polynucleotides which encode HI 305 protein but which differ from the nucleotide sequence set fonh in SEQ ID NO: l by virtue of the degeneracy of the genetic code are also encompassed by the present invention.
- nucleotide sequence as set forth in SEQ ID NO: l which are caused by point mutations or by induced modifications which enhance HI 305 activity, half-life or production level are also included in the invention.
- Polynucleotides encoding HI 305 proteins of other animal species, particularly mammalian species, can be obtained by using portions of SEQ ID NO: l as a probe of a DNA library made from appropriate sources for such other species.
- the isolated polynucleotides of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the HI 305 protein recombinantly.
- an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991
- Many suitable expression control sequences are known in the an. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology lj$5, 537-566 (1990).
- operably linked means enzymatically or chemically ligated to form a covalent bond between the isolated polynucleotide of the invention and the expression control sequence, in such a way that the HI 305 protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
- a number of types of cells may act as suitable host cells for expression of the H1305 protein. Any cell type capable of expressing functional H1305 protein may be used.
- Suitable mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants. HeLa cells, mouse L cells, BHK, HL-60. U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12 or C2C12 cells.
- monkey COS cells Chinese Hamster Ovary (CHO) cells
- human kidney 293 cells human epidermal A431 cells
- human Colo205 cells human Colo205 cells
- CV-1 cells other transformed primate cell lines
- normal diploid cells cell strains derived from in vitro culture of primary tissue, primary explants.
- HeLa cells mouse L cells, BHK, HL-60. U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12 or C2
- the HI 305 protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
- suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
- Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac ® kit), and such methods are well known in the an, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). incorporated herein by reference.
- the HI 305 protein may be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria.
- suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins.
- Suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimu ⁇ um, or any bacterial strain capable of expressing heterologous proteins.
- the HI 305 protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the HI 305 protein.
- the HI 305 protein of the invention may be prepared by growing a culture of transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. The HI 305 protein of the invention can be purified from conditioned media.
- the HI 305 protein can be purified using methods known to those skilled in the an.
- the H1305 protein of the invention can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
- the concentrate can be applied to a purification matrix such as a gel filtration medium.
- an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups.
- the matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.
- a cation exchange step can be employed.
- Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g., S-Sepharose ® columns).
- the purification of the HI 305 protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl ® or Cibacrom blue 3GA Sepharose ® ; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography.
- RP-HPLC reverse-phase high performance liquid chromatography
- hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other aliphatic groups
- the HI 305 protein is purified so that it is substantially free of other mammalian proteins.
- HI 305 and HI 305 related proteins may have an effect on chemotaxis or migration of blood cells, including without limitation eosinophils. basophils, dendritic cells, natural killer cells, neutrophils, monocytes, T cells and mast cells.
- a protein or peptide has "chemotactic activity," as used herein, if it can stimulate, directly or indirectly, the directed orientation or movement of cells, including myeloid and lymphoid cells.
- the protein or peptide has the ability to directly stimulate directed movement of cells.
- H1305 proteins may also be useful for inhibition of viral replication, including without limitation replication of HIV.
- Isolated HI 305 proteins may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier may contain, in addition to H1305 protein and carrier, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the an.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s).
- the characteristics of the carrier will depend on the route of administration.
- the pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2, IL-3.
- the pharmaceutical composition may contain thrombolytic or anti-thrombotic factors such as plasminogen activator and Factor VIII.
- the pharmaceutical composition may further contain other anti-inflammatory agents. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with HI 305 protein, or to minimize side effects caused by the H1305 protein.
- H1305 protein may be included in formulations of the pa ⁇ icular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti- thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine.
- lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent may be included in formulations of the pa ⁇ icular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
- the pharmaceutical composition of the invention may be in the form of a liposome in which HI 305 protein is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which in aqueous solution.
- Suitable lipids for liposomal formulation include, without limitation, monoglycerides. diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the an, as disclosed, for example, in U.S. Patent No. 4.235,871; U.S. Patent No. 4.501,728; U.S. Patent No. 4.837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.
- the term "therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions.
- a meaningful patient benefit e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions.
- the term refers to that ingredient alone.
- the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
- HI 305 protein is administered to a mammal.
- HI 305 protein may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors.
- cytokines, lymphokines, other hematopoietic factors or vaccine components such as antigens or other adjuvants
- HI 305 protein may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially.
- HI 305 protein used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.
- H1305 protein will be in the form of a tablet, capsule, powder, solution or elixir.
- the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant.
- a solid carrier such as a gelatin or an adjuvant.
- the tablet, capsule, and powder contain from about 5 to 95% HI 305 protein, and preferably from about 25 to 90% HI 305 protein.
- a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added.
- the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.
- the pharmaceutical composition contains from about 0.5 to 90% by weight of H1305 protein, and preferably from about 1 to 50% H1305 protein.
- HI 305 protein When a therapeutically effective amount of HI 305 protein is administered by intravenous, cutaneous or subcutaneous injection, HI 305 protein will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
- a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to HI 305 protein an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the an.
- the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.
- the amount of HI 305 protein in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of H1305 protein with which to treat each individual patient. Initially, the attending physician will administer low doses of HI 305 protein and observe the patient's response. Larger doses of HI 305 protein may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not generally increased further.
- the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 ⁇ g to about 10 mg of H1305 protein per kg body weight, more preferably about 0.1 ⁇ g to about 100 ⁇ g of H1305 protein per kg body weight, most preferably about 0.1 ⁇ g to about 10 ⁇ g of H1305 protein per kg body weight.
- the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the HI 305 protein will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
- HI 305 proteins may also be useful for treatment of wounds.
- the protein may be administered as described above, if appropriate. or may be applied in other suitable forms, such as by topical administration in the form of a solution, suspension, ointment, salve, compress and the like.
- HI 305 protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the H1305 protein and which may inhibit H1305 binding to its receptor. Such antibodies are also useful for performing diagnostics assays for HI 305 in accordance with known methods. Such antibodies may be obtained using the entire H1305 protein as an immunogen, or by using fragments of H1305 protein.
- the peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues.
- KLH keyhole limpet hemocyanin
- Neutralizing or non-neutralizing antibodies (preferably monoclonal antibodies) binding to HI 305 protein may also be useful therapeutics for certain tumors and also in the treatment of conditions described above.
- 10 monoclonal antibodies are capable of blocking the ligand binding to the HI 305 protein or may promote clearance of protein from the patient.
- Example Isolation of HI 305 cDNA A partial clone for HI 305 was isolated from a cDNA library made from
- RNA isolated from stimulated human peripheral blood mononuclear cells using methods which are selective for secreted proteins was then used to identify a full-length clone from a PBMC library. Comparison of this sequence to the sequence of the original partial clone confirmed identity and that the isolated cDNA was full-length.
- the full-length clone (H1305, SEQ ID NO:l) was deposited with the Ame ⁇ can Type Culture Collection on December 13, 1995 and assigned accession number ATCC 69968.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Polynucleotides encoding H1305 and related proteins are disclosed. H1305 proteins and methods for their production are also disclosed.
Description
BETA-CHEMOKINE, H1305 (MCP-2)
Field of the Invention The present invention relates to HI 305 proteins, nucleic acids encoding such proteins, and methods of treatment using such proteins.
Background of the Invention
Chemokines are a subclass of cytokines which cause the directed migration or chemotaxis of particular cell populations either to or away from higher concentrations of the chemokine. Many chemokines have been identified which cause migration of major blood cell populations. These factors may be useful for directing the migration of cell populations to areas of desired action or away from areas of unwanted action. It would, therefore, be desirable to identify new chemokines and polynucleotides encoding them.
Summary of the Invention
In developing the present invention, methods were employed which selectively identify polynucleotides which encode secreted proteins. One such polynucleotide was isolated which encodes "HI 305. " In accordance with the present invention, polynucleotides encoding HI 305 and active fragments thereof are disclosed. "HI 305" is used throughout the present specification to refer to both proteins and polynucleotides encoding those proteins and to refer to proteins and polynucleotides from all mammalian species. In certain embodiments, the present invention provides an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO: l from nucleotide 47 to nucleotide 373;
(b) a nucleotide sequence capable of hybridizing to a nucleic acid sequence specified in (a);
(c) a nucleotide sequence varying from the sequence of the nucleotide sequence specified in (a) as a result of degeneracy of the genetic code;
(d) a nucleotide sequence encoding a fragment of the amino acid sequence of SEQ ID NO: 2; and (e) an allelic variant of the nucleotide sequence specified in (a).
Polynucleotides comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 47 to nucleotide 373 are particularly preferred. Preferably, the polynucleotide of the invention encodes a protein having HI 305 activity. In other embodiments the polynucleotide is operably linked to an expression control sequence.
Host cells transformed with the polynucleotides of the invention are also provided, including mammalian cells.
Processes are also provided for producing a HI 305 protein, said processes comprising: (a) growing a culture of the host cell of the invention in a suitable culture medium; and
(b) purifying the HI 305 protein from the culture. Isolated HI 305 protein is also provided which comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2: and
(b) fragments of (a) having HI 305 activity. Proteins comprising the amino acid sequence of SEQ ID NO:2 are particularly preferred. Preferably, the protein has HI 305 activity. Pharmaceuticals composition comprising a HI 305 protein of the invention and a pharmaceutically acceptable carrier are also provided.
Compositions are also disclosed which comprise an antibody which specifically reacts with a H1305 protein of the invention.
Methods of treating a mammalian subject are also provided which comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a HI 305 protein.
Detailed Description of Preferred Embodiments
The inventors of the present application have identified and provided a polynucleotide encoding a H1305 protein. SEQ ID NO: l provides the nucleotide sequence of a cDNA encoding the H1305 protein. SEQ ID NO:2 provides the amino acid sequence of the HI 305 protein predicted from the DNA coding sequence. The amino acid sequence of HI 305 contains known chemokine sequence motifs and shows homology with known chemokines.
Forms of HI 305 protein of less than full length are encompassed within the present invention and may be produced by expressing a corresponding fragment of the polynucleotide encoding the HI 305 protein (SEQ ID NO: l). These corresponding polynucleotide fragments are also pan of the present invention. Modified polynucleotides as described above may be made by standard molecular biology techniques, including site-directed mutagenesis methods which are known in the an or by the polymerase chain reaction using appropriate oligonucleotide primers. A mature form of the H1305 protein, if it differs from the full-length sequence of SEQ ID NO:2, can be produced by expression of the full-length polynucleotide in an appropriate cell line.
For the purposes of the present invention, a protein has "H1305 activity" if it either (1) displays chemoattractant or chemotactic activity in a chemoattraction or chemotaxis assay (preferably an assay in which the corresponding species full- length HI 305 is active), or (2) displays biological activity in a factor-dependent cell proliferation assay (preferably an assay in which the corresponding species full-length H1305 is active), or (3) displays activity in the induction of lymphokine production or effector function in an immune cell functional assay. Examples of effector function include, without limitation, tumoricidal activity, granule release, adhesion molecule expression, and the like. Activity may be monitored using assays known in the art. Chemoattractant or chemotactic activity can also be measured in vivo by injecting protein at a particular site and performing a histological examination of the cell types that migrate to the site of injection. H1305 protein or fragments thereof having H1305 activity may be fused to carrier molecules such as immunoglobulins. For example, HI 305 protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin.
The invention also encompasses allelic variations of the nucleotide sequence as set forth in SEQ ID NO: l , that is, naturally-occurring alternative forms of the isolated polynucleotide of SEQ ID NO: l which also encode HI 305 or HI 305 proteins having HI 305 activity. Also included in the invention are isolated polynucleotides which hybridize to the nucleotide sequence set forth in SEQ ID NO: l under highly stringent (e.g., 0.2xSSC at 65°C). stringent (e.g. 4xSSC at 65CC or 50% formamide and 4xSSC at 42°C), or relaxed (e.g., 4xSSC at 50°C or 30-40% formamide and 4xSSC at 42°C) conditions. Isolated polynucleotides which encode HI 305 protein but which differ from the nucleotide sequence set fonh in SEQ ID NO: l by virtue of the degeneracy of the genetic code are also encompassed by the present invention. Variations in the nucleotide sequence as set forth in SEQ ID NO: l which are caused by point mutations or by induced modifications which enhance HI 305 activity, half-life or production level are also included in the invention. Polynucleotides encoding HI 305 proteins of other animal species, particularly mammalian species, can be obtained by using portions of SEQ ID NO: l as a probe of a DNA library made from appropriate sources for such other species.
The isolated polynucleotides of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the HI 305 protein recombinantly. Many suitable expression control sequences are known in the an. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology lj$5, 537-566 (1990). As defined herein "operably linked" means enzymatically or chemically ligated to form a covalent bond between the isolated polynucleotide of the invention and the expression control sequence, in such a way that the HI 305 protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence. A number of types of cells may act as suitable host cells for expression of the H1305 protein. Any cell type capable of expressing functional H1305 protein may be used. Suitable mammalian host cells include, for example, monkey COS
cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants. HeLa cells, mouse L cells, BHK, HL-60. U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12 or C2C12 cells.
The HI 305 protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the an, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). incorporated herein by reference.
Alternatively, the HI 305 protein may be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimuήum, or any bacterial strain capable of expressing heterologous proteins. The HI 305 protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the HI 305 protein.
The HI 305 protein of the invention may be prepared by growing a culture of transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. The HI 305 protein of the invention can be purified from conditioned media.
The HI 305 protein can be purified using methods known to those skilled in the an. For example, the H1305 protein of the invention can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration
step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g., S-Sepharose® columns). The purification of the HI 305 protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography. Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the HI 305 protein. Some or all of the foregoing purification steps, in various combinations or with other known methods, can also be employed to provide a substantially purified isolated recombinant protein.
Preferably, the HI 305 protein is purified so that it is substantially free of other mammalian proteins.
It is believed that HI 305, active fragments and variants thereof, and HI 305 related proteins (collectively "H1305 proteins") possess chemokine activities. Therefore, HI 305 and HI 305 related proteins may have an effect on chemotaxis or migration of blood cells, including without limitation eosinophils. basophils, dendritic cells, natural killer cells, neutrophils, monocytes, T cells and mast cells. A protein or peptide has "chemotactic activity," as used herein, if it can stimulate, directly or indirectly, the directed orientation or movement of cells, including myeloid and lymphoid cells. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein or peptide has chemotactic activity for cells can be readily deteπnined by employing such protein or peptide in any known assay for cell chemotaxis.
H1305 proteins may also be useful for inhibition of viral replication, including without limitation replication of HIV.
Isolated HI 305 proteins, purified from cells or recombinantly produced, may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to H1305 protein and carrier, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the an. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2, IL-3. IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11. IL-12, IL-13, IL-14, IL- 15, G-CSF, γ-IFN, stem cell factor, and erythropoietin. The pharmaceutical composition may contain thrombolytic or anti-thrombotic factors such as plasminogen activator and Factor VIII. The pharmaceutical composition may further contain other anti-inflammatory agents. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with HI 305 protein, or to minimize side effects caused by the H1305 protein. Conversely, H1305 protein may be included in formulations of the paπicular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti- thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine. lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent. The pharmaceutical composition of the invention may be in the form of a liposome in which HI 305 protein is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides. diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the an, as disclosed, for
example, in U.S. Patent No. 4.235,871; U.S. Patent No. 4.501,728; U.S. Patent No. 4.837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
In practicing the method of treatment or use of the present invention, a therapeutically effective amount of HI 305 protein is administered to a mammal. HI 305 protein may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines, other hematopoietic factors or vaccine components (such as antigens or other adjuvants), HI 305 protein may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering HI 305 protein in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors. Administration of HI 305 protein used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred. When a therapeutically effective amount of HI 305 protein is administered orally, H1305 protein will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the
invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% HI 305 protein, and preferably from about 25 to 90% HI 305 protein. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of H1305 protein, and preferably from about 1 to 50% H1305 protein.
When a therapeutically effective amount of HI 305 protein is administered by intravenous, cutaneous or subcutaneous injection, HI 305 protein will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the an. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to HI 305 protein an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the an. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.
The amount of HI 305 protein in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of H1305 protein with which to treat each individual patient. Initially, the attending physician will administer low doses of HI 305 protein and observe the patient's response. Larger doses of HI 305 protein may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not generally increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 μg to about
10 mg of H1305 protein per kg body weight, more preferably about 0.1 μg to about 100 μg of H1305 protein per kg body weight, most preferably about 0.1 μg to about 10 μg of H1305 protein per kg body weight. The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the HI 305 protein will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
HI 305 proteins may also be useful for treatment of wounds. In such applications, the protein may be administered as described above, if appropriate. or may be applied in other suitable forms, such as by topical administration in the form of a solution, suspension, ointment, salve, compress and the like.
HI 305 protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the H1305 protein and which may inhibit H1305 binding to its receptor. Such antibodies are also useful for performing diagnostics assays for HI 305 in accordance with known methods. Such antibodies may be obtained using the entire H1305 protein as an immunogen, or by using fragments of H1305 protein. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues. Methods for synthesizing such peptides are known in the an, for example, as in R.P. Merrifield, J.Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al.. FEBS Lett. 211. 10 (1987). Neutralizing or non-neutralizing antibodies (preferably monoclonal antibodies) binding to HI 305 protein may also be useful therapeutics for certain tumors and also in the treatment of conditions described above. These neutralizing
10
monoclonal antibodies are capable of blocking the ligand binding to the HI 305 protein or may promote clearance of protein from the patient.
Example Isolation of HI 305 cDNA A partial clone for HI 305 was isolated from a cDNA library made from
RNA isolated from stimulated human peripheral blood mononuclear cells using methods which are selective for secreted proteins. Sequence from this partial clone was then used to identify a full-length clone from a PBMC library. Comparison of this sequence to the sequence of the original partial clone confirmed identity and that the isolated cDNA was full-length. The full-length clone (H1305, SEQ ID NO:l) was deposited with the Ameπcan Type Culture Collection on December 13, 1995 and assigned accession number ATCC 69968.
All patent and literature references cited herein are incoφorated by reference as if fully set forth.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(1) APPLICANT: Racie, Lisa A.
LaVallie, Edward R. McCoy, John
(11) TITLE OF INVENTION: Chemokme H1305 (ill) NUMBER OF SEQUENCES: 2
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genetics Institute, Inc.
(B) STREET: 87 CambπdgePark Drive
(C) CITY: Cambridge
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP. 02140
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.30
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Brown, Scott A.
(B) REGISTRATION NUMBER: 32,724
(C) REFERENCE/DOCKET NUMBER: GI5265 dx) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 498-8224
(B) TELEFAX: (617) 876-5851
(2) INFORMATION FOR SEQ ID NO:1 •
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 411 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(11) MOLECULE TYPE: cDNA (ill) HYPOTHETICAL: NO
(lx) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 47..373
(Xl) SEQUENCE DESCRIPTION: SEQ ID NO:l:
GAATTCGGCC AAAGAGGCTA GAACAACCCA GAAACCTTCA CCTCTC ATG CTG AAG 55
Met Leu Lys
1
CTC ACA CCC TTG CCC TCC AAG ATG AAG GTT TCT GCA GCG CTT CTG TGC 103 Leu Thr Pro Leu Pro Ser Lys Met Lys Val Ser Ala Ala Leu Leu Cys 5 10 15
CTG CTG CTC ATG GCA GCC ACT TTC AGC CCT CAG GGA CTT GCT CAG CCA 151 Leu Leu Leu Met Ala Ala Thr Phe Ser Pro Gin Gly Leu Ala Gin Pro 20 25 30 35
GAT TCA GTT TCC ATT CCA ATC ACC TGC TGC TTT AAC GTG ATC AAT AGG 199 Asp Ser Val Ser lie Pro lie Thr Cys Cys Phe Asn Val lie Asn Arg 40 45 50
AAA ATT CCT ATC CAG AGG CTG GAG AGC TAC ACA AGA ATC ACC AAC ATC 247 Lys lie Pro lie Gin Arg Leu Glu Ser Tyr Thr Arg lie Thr Asn lie 55 60 65
CAA TGT CCC AAG GAA GCT GTG ATC TTC AAG ACC CAA CGG GGC AAG GAG 295 Gin Cys Pro Lys Glu Ala Val lie Phe Lys Thr Gin Arg Gly Lys Glu 70 75 80
GTC TGT GCT GAC CCC AAG GAG AGA TGG GTC AGG GAT TCC ATG AAG CAT 343 Val Cys Ala Asp Pro Lys Glu Arg Trp Val Arg Asp Ser Met Lys His 85 90 95
CTG GAC CAA ATA TTT CAA AAT CTG AAG CCA TGAGCCTTCA TACATGGACT 393 Leu Asp Gin He Phe Gin Asn Leu Lys Pro 100 105
GAGAGTCAGA GCTTGAAG 411
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 109 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Leu Lys Leu Thr Pro Leu Pro Ser Lys Met Lys Val Ser Ala Ala
1 5 10 15
Leu Leu Cys Leu Leu Leu Met Ala Ala Thr Phe Ser Pro Gin Gly Leu 20 25 30
Ala Gin Pro Asp Ser Val Ser He Pro He Thr Cys Cys Phe Asn Val 35 40 45
He Asn Arg Lys He Pro He Gin Arg Leu Glu Ser Tyr Thr Arg He 50 55 60
Thr Asn He Gin Cys Pro Lys Glu Ala Val He Phe Lys Thr Gin Arg 65 70 75 80
Gly Lys Glu Val Cys Ala Asp Pro Lys Glu Arg Trp Val Arg Asp Ser 85 90 95
Met Lys His Leu Asp Gin He Phe Gin Asn Leu Lys Pro 100 105
Claims
1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:l from nucleotide 47 to nucleotide 373; (b) a nucleotide sequence capable of hybridizing to a nucleic acid sequence specified in (a);
(c) a nucleotide sequence varying from the sequence of the nucleotide sequence specified in (a) as a result of degeneracy of the genetic code;
(d) a nucleotide sequence encoding a fragment of the amino acid sequence of SEQ ID NO:2; and
(e) an allelic variant of the nucleotide sequence specified in (a).
2. The polynucleotide of claim 1 wherein said nucleotide sequence encodes a protein having HI 305 activity.
3. The polynucleotide of claim 1 wherein said nucleotide sequence is operably linked to an expression control sequence.
4. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:l from nucleotide 47 to nucleotide 373.
5. A host cell transformed with the polynucleotide of claim 3.
6. The host cell of claim 5, wherein said cell is a mammalian cell.
7. A process for producing a HI 305 protein, said process comprising:
(a) growing a culture of the host cell of claim 5 in a suitable culture medium; and
(b) purifying the HI 305 protein from the culture.
8. An isolated HI 305 protein comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2; and
(b) fragments of (a) having HI 305 activity.
9. The protein of claim 8 comprising the amino acid sequence of SEQ ID NO:2.
10. A pharmaceutical composition comprising a HI 305 protein of claim 8 and a pharmaceutically acceptable carrier.
11. A HI 305 protein produced according to the process of claim 7.
12. A composition comprising an antibody which specifically reacts with a HI 305 protein of claim 8.
13. A method of treating a mammalian subject comprising administering a therapeutically effective amount of a composition of claim 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15326/97A AU1532697A (en) | 1996-01-12 | 1997-01-10 | Beta-chemokine, h1305 (mcp-2) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58639596A | 1996-01-12 | 1996-01-12 | |
US08/586,395 | 1996-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997025427A1 true WO1997025427A1 (en) | 1997-07-17 |
Family
ID=24345548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/000379 WO1997025427A1 (en) | 1996-01-12 | 1997-01-10 | Beta-chemokine, h1305 (mcp-2) |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1532697A (en) |
WO (1) | WO1997025427A1 (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001554A2 (en) * | 1996-07-09 | 1998-01-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998001469A2 (en) * | 1996-06-19 | 1998-01-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998001552A2 (en) * | 1996-07-09 | 1998-01-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998002459A1 (en) * | 1996-07-15 | 1998-01-22 | Incyte Pharmaceuticals, Inc. | Human monocyte chemotactic proprotein |
WO1998004694A2 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998004696A1 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998004695A1 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998004693A2 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998005781A1 (en) * | 1996-08-02 | 1998-02-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998005776A2 (en) * | 1996-08-02 | 1998-02-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007856A1 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007859A2 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007853A1 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007855A2 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998014575A1 (en) * | 1996-10-04 | 1998-04-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them________________________________________________________________________________________________________________________________________________ |
WO1998014576A2 (en) * | 1996-10-04 | 1998-04-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998014470A2 (en) * | 1996-10-04 | 1998-04-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998017687A2 (en) * | 1996-10-25 | 1998-04-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998020125A1 (en) * | 1996-11-06 | 1998-05-14 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998020130A2 (en) * | 1996-11-01 | 1998-05-14 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998021332A2 (en) * | 1996-11-15 | 1998-05-22 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998024905A2 (en) * | 1996-12-06 | 1998-06-11 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998030695A2 (en) * | 1997-01-09 | 1998-07-16 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998031802A2 (en) * | 1997-01-21 | 1998-07-23 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998032853A2 (en) * | 1997-01-24 | 1998-07-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998033916A2 (en) * | 1997-01-31 | 1998-08-06 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998037094A2 (en) * | 1997-02-24 | 1998-08-27 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998040486A2 (en) * | 1997-03-14 | 1998-09-17 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1999016876A1 (en) * | 1997-09-29 | 1999-04-08 | Applied Research Systems Ars Holding N.V. | Amino-terminally truncated mcp-2 as chemokine antagonists |
WO1999028472A1 (en) * | 1997-11-27 | 1999-06-10 | Korea Green Cross Corporation | A cDNA ENCODING C6 β-CHEMOKINE LEUKOTACTIN-1(Lkn-1) ISOLATED FROM HUMAN |
WO1999028462A3 (en) * | 1997-12-03 | 1999-10-14 | Genentech Inc | Polypeptides and nucleic acids encoding the same |
WO2000036102A2 (en) * | 1998-12-16 | 2000-06-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000056889A2 (en) * | 1999-03-23 | 2000-09-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1191101A2 (en) * | 1997-12-11 | 2002-03-27 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
US6984519B2 (en) | 2000-03-01 | 2006-01-10 | Genetech, Inc. | Nucleic acids encoding peptides that induce chondrocyte redifferentiation |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7193045B2 (en) | 1998-05-15 | 2007-03-20 | Genetech, Inc. | Polypeptides that induce cell proliferation |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7435793B2 (en) | 1998-05-15 | 2008-10-14 | Genentech, Inc. | Peptides that induce chondrocyte redifferentiation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032481A1 (en) * | 1995-04-13 | 1996-10-17 | Incyte Pharmaceuticals, Inc. | New chemokine expressed in eosinophils |
WO1996040923A1 (en) * | 1995-06-07 | 1996-12-19 | Icos Corporation | Macrophage derived chemokine and chemokine analogs |
-
1997
- 1997-01-10 AU AU15326/97A patent/AU1532697A/en not_active Abandoned
- 1997-01-10 WO PCT/US1997/000379 patent/WO1997025427A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032481A1 (en) * | 1995-04-13 | 1996-10-17 | Incyte Pharmaceuticals, Inc. | New chemokine expressed in eosinophils |
WO1996040923A1 (en) * | 1995-06-07 | 1996-12-19 | Icos Corporation | Macrophage derived chemokine and chemokine analogs |
Non-Patent Citations (4)
Title |
---|
CHANG, H. ET AL.: "Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family", INTERNATIONAL IMMUNOLOGY, vol. 1, 1989, pages 388 - 399, XP000673182 * |
CLARK-LEWIS I ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF CHEMOKINES", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 57, no. 5, May 1995 (1995-05-01), pages 703 - 711, XP000605180 * |
VAN DAMME, J. ET AL.: "Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonginig to the chemokine family", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 176, July 1992 (1992-07-01), pages 59 - 65, XP000673185 * |
WEMPE, F. ET AL.: "Cloning of the gene for bovine monocyte chemoattractant protein-2", DNA AND CELL BIOLOGY, vol. 13, January 1994 (1994-01-01), pages 1 - 8, XP000673202 * |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001469A3 (en) * | 1996-06-19 | 1998-02-19 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998001469A2 (en) * | 1996-06-19 | 1998-01-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998001552A2 (en) * | 1996-07-09 | 1998-01-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998001554A2 (en) * | 1996-07-09 | 1998-01-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998001552A3 (en) * | 1996-07-09 | 1998-03-05 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998001554A3 (en) * | 1996-07-09 | 1998-03-05 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
US5965388A (en) * | 1996-07-09 | 1999-10-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998002459A1 (en) * | 1996-07-15 | 1998-01-22 | Incyte Pharmaceuticals, Inc. | Human monocyte chemotactic proprotein |
WO1998004695A1 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998004693A3 (en) * | 1996-07-26 | 1999-08-26 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998004694A3 (en) * | 1996-07-26 | 1998-04-30 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998004693A2 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998004696A1 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998004694A2 (en) * | 1996-07-26 | 1998-02-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998005781A1 (en) * | 1996-08-02 | 1998-02-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998005776A3 (en) * | 1996-08-02 | 1998-05-14 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998005776A2 (en) * | 1996-08-02 | 1998-02-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5985602A (en) * | 1996-08-14 | 1999-11-16 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007855A3 (en) * | 1996-08-23 | 1998-05-07 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998007859A2 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5965693A (en) * | 1996-08-23 | 1999-10-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007856A1 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5981222A (en) * | 1996-08-23 | 1999-11-09 | Genetics Institute, Inc. | Human semaphorin E, secreted proteins and polynucleotides encoding them |
WO1998007855A2 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007853A1 (en) * | 1996-08-23 | 1998-02-26 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998007859A3 (en) * | 1996-08-23 | 1998-05-14 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998014576A2 (en) * | 1996-10-04 | 1998-04-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998014470A3 (en) * | 1996-10-04 | 1998-05-28 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998014575A1 (en) * | 1996-10-04 | 1998-04-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them________________________________________________________________________________________________________________________________________________ |
WO1998014576A3 (en) * | 1996-10-04 | 1998-07-16 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998014470A2 (en) * | 1996-10-04 | 1998-04-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998017687A3 (en) * | 1996-10-25 | 1998-07-30 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998017687A2 (en) * | 1996-10-25 | 1998-04-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998020130A3 (en) * | 1996-11-01 | 1998-07-30 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998020130A2 (en) * | 1996-11-01 | 1998-05-14 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998020125A1 (en) * | 1996-11-06 | 1998-05-14 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998021332A3 (en) * | 1996-11-15 | 1998-08-06 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998021332A2 (en) * | 1996-11-15 | 1998-05-22 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998024905A3 (en) * | 1996-12-06 | 1998-09-17 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998024905A2 (en) * | 1996-12-06 | 1998-06-11 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998030695A2 (en) * | 1997-01-09 | 1998-07-16 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998030695A3 (en) * | 1997-01-09 | 1998-11-12 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998031802A2 (en) * | 1997-01-21 | 1998-07-23 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998031802A3 (en) * | 1997-01-21 | 1998-11-19 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998032853A2 (en) * | 1997-01-24 | 1998-07-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998032853A3 (en) * | 1997-01-24 | 1999-01-07 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998033916A3 (en) * | 1997-01-31 | 1998-12-03 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998033916A2 (en) * | 1997-01-31 | 1998-08-06 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5965397A (en) * | 1997-01-31 | 1999-10-12 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998037094A3 (en) * | 1997-02-24 | 1998-11-05 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998037094A2 (en) * | 1997-02-24 | 1998-08-27 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5976837A (en) * | 1997-03-14 | 1999-11-02 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
WO1998040486A3 (en) * | 1997-03-14 | 1998-12-03 | Genetics Inst | Secreted proteins and polynucleotides encoding them |
WO1998040486A2 (en) * | 1997-03-14 | 1998-09-17 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7700087B2 (en) | 1997-09-11 | 2010-04-20 | Cambridge Enterprise Limited | Compounds and methods to inhibit or augment an inflammatory response |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
CZ299478B6 (en) * | 1997-09-29 | 2008-08-06 | Laboratoires Serono Sa | Amino-terminally truncated MCP-2, DNA molecule, expression vector, host cell and pharmaceutical composition |
US6905676B2 (en) | 1997-09-29 | 2005-06-14 | Applied Research Systems Ars Holding N.V. | Amino-terminally truncated MCP-2 as chemokine antagonists |
US7338653B2 (en) | 1997-09-29 | 2008-03-04 | Laboratoires Serono Sa | Amino-terminally truncated MCP-2 as chemokine antagonists |
WO1999016876A1 (en) * | 1997-09-29 | 1999-04-08 | Applied Research Systems Ars Holding N.V. | Amino-terminally truncated mcp-2 as chemokine antagonists |
WO1999028472A1 (en) * | 1997-11-27 | 1999-06-10 | Korea Green Cross Corporation | A cDNA ENCODING C6 β-CHEMOKINE LEUKOTACTIN-1(Lkn-1) ISOLATED FROM HUMAN |
WO1999028462A3 (en) * | 1997-12-03 | 1999-10-14 | Genentech Inc | Polypeptides and nucleic acids encoding the same |
EP1191101A2 (en) * | 1997-12-11 | 2002-03-27 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
EP1191101A3 (en) * | 1997-12-11 | 2002-08-28 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
US7193045B2 (en) | 1998-05-15 | 2007-03-20 | Genetech, Inc. | Polypeptides that induce cell proliferation |
US7435793B2 (en) | 1998-05-15 | 2008-10-14 | Genentech, Inc. | Peptides that induce chondrocyte redifferentiation |
WO2000036102A3 (en) * | 1998-12-16 | 2000-11-09 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000036102A2 (en) * | 1998-12-16 | 2000-06-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
EP1688430A3 (en) * | 1999-03-23 | 2006-11-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000056889A3 (en) * | 1999-03-23 | 2001-04-26 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000056889A2 (en) * | 1999-03-23 | 2000-09-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6984519B2 (en) | 2000-03-01 | 2006-01-10 | Genetech, Inc. | Nucleic acids encoding peptides that induce chondrocyte redifferentiation |
Also Published As
Publication number | Publication date |
---|---|
AU1532697A (en) | 1997-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997025427A1 (en) | Beta-chemokine, h1305 (mcp-2) | |
JP3367581B2 (en) | Novel polypeptide, method for producing the same, DNA encoding the polypeptide, vector comprising the DNA, and host cells transformed with the vector | |
US6214559B1 (en) | Methods of identifying inhibitors of binding of IL-13 to the IL-13 receptor chain | |
Brown et al. | A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. | |
JP3677288B2 (en) | Macrophage inflammatory protein-3, -4 and -1 [lower γ] | |
AU727480B2 (en) | Human CTLA-8 and uses of CTLA-8-related proteins | |
US6043344A (en) | Human CTLA-8 and uses of CTLA-8-related proteins | |
JP2893653B2 (en) | Natural killer cell stimulating factor | |
JPH01502397A (en) | M-CSF production method | |
US5989867A (en) | DNA encoding IL-10-like homologue; related reagents | |
WO1997004097A9 (en) | Human ctla-8 and uses of ctla-8-related proteins | |
EP0733069A1 (en) | Purified primate ctla-8 antigens and related reagents | |
WO1991004274A1 (en) | Method for inhibiting growth of stem cells | |
AU2002324249B2 (en) | Interleukin-18 mutants, their production and use | |
DE60036937T2 (en) | HUMANE GIL-19 / AE289 PROTEINS AND POLYNUCLEOTIDE CODING THEREOF | |
JP2002509432A (en) | Mammalian cytokine-like factor 7 | |
AU758576B2 (en) | Chemokines with amino-terminal modifications | |
AU2002324249A1 (en) | Interleukin-18 mutants, their production and use | |
JP2003047492A (en) | Human chemokine beta-9 | |
JPH10500300A (en) | Monocyte chemotactic protein-4 | |
US5641657A (en) | DNA encoding an interleukin-6 splice variant | |
US5728548A (en) | Retinoid receptor-1 (RR1) and DNA encoding RR1 | |
CA2255906A1 (en) | Human interleukin-1j and antagonists thereof | |
US6084071A (en) | Human L105 polypeptides and polynucleotides encoding same | |
CA2295982A1 (en) | Human l105 proteins and polynucleotides encoding same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97525411 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |